Vedanta Biosciences

Vedanta Biosciences

A biotechnology company that develops medicines based on live bacterial consortia that can colonize the human intestine.

Vedanta Biosciences is a biotechnology company that develops medicines based on live bacterial consortia that can colonize the human intestine that is headquartered in Cambridge, Massachusetts. Vedanta Biosciences was launched by PureTech Health and was founded by Ruslan Medzhitov, Alexander Rudensky, Dan Littman, Kenya Honda, and Brett Finlay.

Funding

Series C

On December 24, 2018 Vedanta Biosciences completed their series C funding round with $27 million in funding from Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health. The company plans on using the funding to develop its product candidates derived from the microbiome.

Series C-2

On May 13, 2019 Vedanta Biosciences completed their series C-2 funding round raising $45.5 million in funding from JSR Corporation, Shumway Capital, SymBiosis LLC, and Partners Investment Co., Ltd.. The CEO and co-founder of Vedanta Biosciences, Bernat Olle, made the following statement regarding how the company plans on using the funding:

This financing will enable us to continue to advance defined bacterial consortia as a new modality, including generating clinical readouts in multiple therapeutic areas, and we are grateful to our new and existing investors for their support.

On September 23, 2019 Vedanta Biosciences announced expanding their series C-2 funding round with $16.6 million in funding from QUAD Investment Management, SV Investment Corp., Shinhan Investment-Private Equity, Shinhan Capital-Yeollim Partners, Partners Investment Co., Ltd, FC Capital, and SymBiosis LLC. The company plans on using their additional funding to accelerate the development of its product pipeline.

Timeline

September 23, 2019

Vedanta Biosciences raises a $16,600,000 series C round from Shinhan Private Equity and QUAD Investment Management.

May 24, 2019

Vedanta Biosciences raises a $45,500,000 series C round from JSR Corporation and Shumway Capital.

December 24, 2018

Vedanta Biosciences raises a $27,000,000 series C round from Rock Springs Capital, Bill & Melinda Gates Foundation and Seventure Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
June 9, 2020
BioSpace
Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD) - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.